Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[02/04/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.3 Notifications referring to situation on 27, 28 and 29 March 2019Threshold crossed: 5%Latest holding: 5,38 %Brussels Belgium, 2 April 2019 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 3 transparency... See more
 
UCB [BE0003739530/UCB]   
[01/04/2019]

UCB : UCB Media Room: Midazolam Nasal Spray

UCB to provide additional information to the US FDA regarding midazolam nasal spray submissionBrussels Belgium & Atlanta, Georgia U.S. 07:00, 01 April 2019: UCB announced today that the U.S. Food and Drug Administration FDA has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for... See more
 
UCB [BE0003739530/UCB]   
[29/03/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notification BlackRock, Inc.Notification referring to situation on 25 March 2019Threshold crossed: 5%Latest holding: 5.23 %Brussels Belgium, 29 March 2019 – 20:00 CET – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification... See more
 
UCB [BE0003739530/UCB]   
[28/03/2019]

UCB : UCB Media Room: Cimzia nr-axSpA US FDA Approval

CIMZIA® certolizumab pegol is Now the First and Only U.S. FDAApproved Treatment forNonRadiographic Axial SpondyloarthritisPatients living with nonradiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatmentFDA approval was based on the CAXSPAND Phase 3 study in adults with nonradiographic axial... See more
 
UCB [BE0003739530/UCB]   
[19/03/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notification BlackRock, Inc.Notification referring to situation on 13 March 2019Threshold crossed: 5%Latest holding: 5.40 %Brussels Belgium, 19 March 2019 – 20:00 CET – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification... See more
 
UCB [BE0003739530/UCB]   
[13/03/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notification UCB SA/NVNotification referring to situation on 8 March 2019Threshold crossed: 3%Latest holding: 3.07%Brussels Belgium, 13 March 2019 – 20:00 CET – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.The... See more
 
UCB [BE0003739530/UCB]   
[02/03/2019]

UCB : UCB Media Room: AAD bimekizumab

Bimekizumab Demonstrated LongTerm Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement PASI90 over 60 weeks with bimekizumabThese positive results mark the longestterm data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks... See more
 
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...